Traditional cardiovascular disease (CVD) risk factors do

Size: px
Start display at page:

Download "Traditional cardiovascular disease (CVD) risk factors do"

Transcription

1 SPECIAL REPORT: RISK FACTORS FOR CARDIOVASCULAR DISEASE Are Additional Lipid Measures Useful? Ryan D. Bradley, ND; and Erica B. Oberg, ND, MPH Abstract Total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are the well-established standards by which clinicians identify individuals at risk for coronary artery disease (CAD), yet nearly 50% of people who have a myocardial infarction have normal cholesterol levels. Measurement of additional biomarkers may be useful to more fully stratify patients according to disease risk. The typical lipid panel includes TC, LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TGs). Emerging biomarkers for cardiovascular risk include measures of LDL-C pattern, size, and density; LDL particle number; lipoprotein(a); apolipoproteins (apoa1 and apob100 being the most useful); C-reactive protein; and lipoprotein-associated phospholipase A 2. Some of these emerging biomarkers have been proven to add to, or be more accurate than, traditional risk factors in predicting coronary artery disease and, thus, may be useful for clinical decision-making in high-risk patients and in patients with borderline traditional risk factors. However, we still believe that until treatment strategies can uniquely address these added risk factors ie, until protocols to rectify unhealthy findings are shown to improve cardiovascular outcomes healthcare providers should continue to focus primarily on helping patients reach optimal LDL-C, HDL-C, and TG levels. Traditional cardiovascular disease (CVD) risk factors do not fully explain individual or population risk for the development of CVD. Total cholesterol (TC) and lowdensity lipoprotein cholesterol (LDL-C) are the well-established standards by which clinicians identify individuals at risk for coronary artery disease (CAD), yet nearly 50% of people who have a myocardial infarction (MI) have normal cholesterol levels. 1 It is desirable for the clinician to more fully stratify patients according to disease risk, while simultaneously being able to offer effective treatments to reduce that risk. Over the past decade, more precise tools for measurement of lipid density the size and number of lipoprotein particles, markers of inflammation, etc have been developed in attempts to develop riskprediction tools, explore new treatments, and better understand the protective benefits of current treatment options. Whether these tools have added value at the present time is the subject of this article. Decision-making challenges are created because commercial development of laboratory assays to measure emerging risk factors have introduced many of these testing options into the clinical environment. Clinicians want to educate patients and reduce risk as precisely as possible; yet, using novel clinical testing prematurely ie, before testing has been fully proven to be relevant in risk stratification or before using test results translates into improved clinical outcomes accrues costs to the general healthcare system and may cause both doctors and patients to avoid research-tested treatments for risk reduction. For example, patients are often nervous about taking proven treatments to lower LDL and instead are excited about taking nutritional supplementation based on the premature use of genetic testing, despite a lack of data based on such genetic testing that show improvements in hard clinical outcomes. Additionally, patients can become attached to conjectures that traditional risk factors are not important, leaving the clinician in the difficult position of trying to explain the importance of controlling traditional risk factors, despite the patient s learned bias against such control; this is a missing the forest for the trees phenomenon. In making the decision whether to test for, and whether to treat based on, emerging risk factors, we recommend the following considerations: 1. Does the test result provide valid, independent information on my patient s cardiovascular risk? 2. Is there unique treatment available for this risk factor that is safe, well researched, and accessible? 3. Will testing and treatment for the risk factor somehow distract me or my patient from addressing his or her risky profile based on well-established risk factors? 4. Does treatment impact hard clinical outcomes, ie, cardiovascular events and death, not just biomarker reduction? This article reviews the contribution that additional biomarkers make to identifying coronary artery disease (CAD) risk. We have limited this review to biomarkers that are both part of standard laboratory offerings and, when medically appropriate, covered by insurance. In a subsequent article, we will prioritize treatment options according to potential benefit for risk-factor reduction. Traditional Risk Factors and Treatments The typical lipid panel includes TC, LDL-C (preferably measured directly rather than calculated), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TGs) (see Table 1). 18 Integrative Medicine Vol. 7, No. 6 Dec 2008/Jan 2009 Bradley and Oberg Cardiovascular Disease

2 Table 1. Traditional Lipid Panel and Recommended Treatment Goals for Cardiovascular Disease Prevention 34 Total Cholesterol Desirable (low) < 200 mg/dl Borderline high mg/dl High 240 mg/dl or greater HDL Cholesterol Desirable (high) > 60 mg/dl Acceptable mg/dl Low < 40 mg/dl LDL Cholesterol Desirable (low) < 100 mg/dl Acceptable mg/dl Borderline high mg/dl High mg/dl Very high 190 mg/dl or greater Triglycerides Desirable (low) < 150 mg/dl Borderline high mg/dl High mg/dl Very high 500 mg/dl or greater TC in isolation is of little clinical value, although it is frequently used in combination with HDL for risk stratification. Desired values are low, < 200 mg/dl. LDL-C, largely because of historical use (since 1885) both clinically and in population research, is still the primary biomarker used to measure cardiovascular risk. It is a measure of the cholesterol content of lipoproteins. Desired values are low, < 100 mg/dl. While we now know that LDL-C is a fairly imprecise marker, it is worth recalling that, by using it, evidence of a causal relationship in the pathogenesis of CAD is shown; patients with homozygous familial hypercholesterolemia, who generally have LDL-C levels of > 500 mg/dl, can experience MI and ischemic death in the first decade of life. 2 Most cholesterollowering treatment strategies (such as statins) seem to demonstrate their primary benefit in reducing mortality and cardiovascular events by reducing LDL-C. 3 Very low-density lipoproteins (VLDLs) are secreted from the liver, transport TGs, and are precursors of LDL-C. VLDLs are overproduced in people with insulin resistance and diabetes. 2 Treatment strategies that reduce fatty infiltration of the liver, including dietary change, physical activity, insulin sensitization, and pharmacologic TG reduction, are appropriate. Achieving desired control of TGs and LDL will lead to desirable VLDL levels, and thus VLDL does not require separate measurement. HDL-C is involved in reverse cholesterol transport; ie, the transfer of cholesterol from peripheral cells to the liver, to be secreted as bile acids. Desired values are high, > 60 mg/dl. The concentration of HDL-C has a strong inverse relationship to the incidence of CVD. This protective effect is due not only to its promotion of reverse cholesterol transport from vascular walls to the liver, but also to its anti-inflammatory, antioxidant, and antithrombotic effects. When it comes to treatment, niacin is one of few lipid-lowering treatments praised for its ability to raise levels of HDL-C. Clinical trials of niacin have demonstrated reduction of intima-media thickness (IMT) in the vascular wall, suggesting regression of atherosclerotic plaque; this effect appears to be directly correlated with HDL-C concentration. 4 The independent contribution of TGs to cardiovascular risk remains controversial, mostly due to inconsistent data based on fasting TG levels. Interestingly, 3 recent evaluations in large, population-based cohorts suggest non-fasting TG concentration is an independent risk factor for MI, ischemic heart disease, and cardiovascular-related death. 5-7 Although the exact mechanism for this increased risk is unknown, postprandial hyperlipemia is known to contribute to endothelial dysfunction, an earlier, yet cumulative, step in artherogenesis. 8 LDL-C and HDL-C: Pattern, Size, and Density Two patterns predominate and are used to describe the average size of LDL particles. Pattern A refers to a preponderance of large LDL particles, while Pattern B refers to a preponderance of small LDL particles; a minority of individuals displays an intermediate or mixed pattern. Some commercially available assays further subdivide LDL-C into 7 distinct designations based on particle size. 9,10 Some data suggest that small, dense LDL-Cs are more atherogenic than their large, buoyant counterparts; thus, pattern recognition may allow more-precise risk stratification. Suggested mechanisms of small, dense LDL-C s increased atherogenicity include their increased susceptibility to oxidation, reduced affinity to LDL receptors, and reduced hepatic clearance. 11 In hyperlipemic environments ie, in individuals with elevated serum TGs and free fatty acids enzymatic changes to large LDL particles (via cholesteryl ester-transfer protein [CETP]) result in TG-rich, cholesterol-poor, small, dense LDLs. Hence, small, dense LDL particles are known to predominate in a TG-rich environment. Small LDL particles have been shown to be positively associated with non-fasting TGs and inversely associated with HDL-C. 12 In multivariate prediction models, levels of HDL, TGs, and insulin were all independent predictors of small, dense LDL particles. 13 Given these associations with risk factors that clinicians are already routinely measuring, the question becomes: Does LDL-C pattern, as opposed to LDL-C presence only, contribute independently to our assessment of CAD risk? The 4637-men Quebec Cardiovascular Study found, after adjustment for systolic blood pressure, medication use, and family history, an increased odds ratio of 2.5 (95% CI: ) for ischemic events in individuals with a small, dense LDL-C pattern. 14 Compared to men in the cohort without ischemic events, the former individuals had significantly lower mean LDL-C size (P<.001) and an increased proportion of very small LDL-C sizes. 15 The relationship between LDL-C pattern and carotid atherosclerosis (measured by IMT) was also tested in the Multiethnic Study of Atherosclerosis, a cohort of 5538 multiethnic participants, with much different results from those above. After standard adjustments for age, sex, race, hypertension, and smoking, small LDL-particle concentrations, but not large LDL-particle concentrations, were significantly associated with increased Bradley and Oberg Cardiovascular Disease Integrative Medicine Vol. 7, No. 6 Dec 2008/Jan

3 IMT. This finding was similar to other studies. However, when the data were analyzed looking at the relationship between concentration of large LDL within strata of small LDLs, IMT was positively associated with increasing concentrations of both small and large LDL-particle concentration. Said differently, IMT increased with increasing quartiles of small LDL concentration yet also increased with increasing large LDL concentration within each quartile of small LDL. On a per-particle basis in this study, large LDL-Cs actually became more strongly associated with IMT than did small LDL-Cs! This study was the first to control for interclass correlations between particle patterns and thus more precisely describes interclass correlations between lipoprotein particles; it does not support a unique association between small LDL particles and atherosclerosis. 16 Given the proven high correlation between small, dense LDL ie, Pattern B, with elevated TGs and reduced HDL-C and given the inclusion of TGs and HDL-C on standard lipid panels, we believe that many clinicians can gather nearly equivalent information to that provided by these newer lipid-density profiles by simply understanding these relationships and using routine lipid tests. That is to say, if a patient has high TGs and low HDL-C, you can assume high numbers of small, dense LDLs just because you understand the effects of TGs on lipoprotein density. In addition, LDL-C remains a driving force in the development of atherosclerosis independent of particle size. If you haven t already guessed, the inter-relatedness of lipid measurements in cardiovascular risk reduction cannot be ignored. As mentioned, TGs directly impact LDL density and size. TGs also have a similar effect on HDL-C: As with LDL-C, TG-rich HDLs are formed by the action of CETP creating smaller, and more-dense, HDL particles; small, dense HDL particles (HDL-3) are catabolized more quickly from circulation and thus do not remain involved in reverse cholesterol transport from the periphery. 17, 18 In hypertriglyceridemia, the rate of HDL synthesis remains constant while the rate of HDL catabolism increases, resulting in lower quantities of circulating HDL cholesterol. 18 Additionally, several studies have demonstrated that HDL-3 has reduced antioxidant action in its ability to protect LDL cholesterol from oxidation; even in healthy individuals, attenuated antioxidant response was proportional to TG concentration in the HDL particle. 19, 20 Because of these inter-relationships, treating high TGs is paramount to both (1) increasing quantities of HDL cholesterol (by reducing its clearance), and (2) maintaining nonoxidized LDL cholesterol (by maintaining a larger, morebuoyant HDLpattern). LDL Lipoprotein Particle Number LDL particle number (LDL-P) is a measure of the number of lipoprotein particles independent of the quantity of lipid within the cholesterol particle; ie, LDL-P measures the number of individual particles, not a concentration like LDL-C. It is measured using nuclear magnetic resonance technology and is unaffected by fasting status. 21 Higher LDL-P measures have been associated with a higher risk of CAD. This might simply be because there are more particles susceptible to oxidation in circulation.* There are suggestions, but not definitive proof, that reducing LDL-P increases intra-ldl antioxidant capacity. The European Prospective Investigation of Cancer (EPIC)- Norfolk cohort, a study that has followed participants (men and women aged years) over 6 years, evaluated associations between LDL-P and risk of CAD. Compared to controls, cases of CAD had a higher number of LDL particles (LDL-P P<.0001), smaller average LDL-particle size (P=.002), and higher concentrations of small LDL particles (P<.0001). 22 Once again, small, dense LDL-C were positively associated with TG and negatively associated with HDL. In another study investigating incident angina and MI with LDL-P, females, but not males, had a significantly increased odds ratio for incident MI and angina for higher LDL-P but not for LDL size after adjustment for LDL, age, and race. Males had increased (but not significant) point estimates showing the same relationship. 23 Of note, LDL-P and non-hdl-c (ie, TC minus HDL-C, or, specifically, LDL-C plus VLDLs), added equivalently to Framingham-predicted CAD risk stratification, thus reducing our enthusiasm for this additional measurement when TC and HDL-C are routinely available. 22 Based on these results, LDL-P is becoming recognized as a more-precise measure of LDL-related risk and, as it becomes more available, is likely to replace LDL-C in risk-stratification tools. Clinical availability is currently limited; however, Medicare recently began reimbursing for regular testing of LDL-P in highrisk patients, so we should see availability increase soon. There are no novel treatments based on LDL-P at this time, and data shows therapies that lower LDL-C lower LDL-P as well. Apolipoproteins Apolipoproteins are the protein components of plasma lipoproteins. Several different apolipoproteins have been identified and numbered; however, apob48, apob100, and apoa are the most commonly referenced. ApoB48 is associated with LDL particles that transport dietary cholesterol to the liver for processing. ApoB100 is found in lipoproteins originating from the liver (eg, LDL and VLDL); it transports these lipoproteins and, also, TGs to the periphery. In addition, ApoB100 is involved with the binding of LDL particles to the vascular wall, implicating itself as a key player in the development of atherogenic plaques. Importantly, there is one apob100 molecule per hepatic-derived lipoprotein. Hence, it is possible to quantify the number of LDL/VLDL particles by noting the total apob100 concentration. Measurement of apob100 has been shown in nearly all studies to outperform LDL-C and non-hdl-c as a predictor of CAD events and as an index of residual CAD risk, perhaps due to differences in measurement sensitivity between measurement methodologies. Direct measurement of apolipoproteins is superior to calculated lipid measurements. Yet, currently, apob100 measurement is more costly than routine measurements and, because apob100 is so closely associated with non-hdl-c (which, *Authors Note: We use the analogy of bullets in a revolver. The more bullets (LDL-P) in the chamber (blood), the more likely the gun will fire (will oxidize) when you pull the trigger (make less-optimal dietary choices). 20 Integrative Medicine Vol. 7, No. 6 Dec 2008/Jan 2009 Bradley and Oberg Cardiovascular Disease

4 as mentioned previously, can be estimated by TC minus HDL-C), our enthusiasm for the clinical use of this test is limited. 24 For its part, apoa is associated with HDL particles; the 2 major proteins in HDL are apoai and apoaii. Of these, apoai has more frequently been used to estimate HDL-C, but, in contrast to apob100, apoai is not unique to HDL and so the ratio of apoai to HDL is not 1 to Recently, it has been suggested that the apob100:apoai ratio be widely adopted as a risk marker or treatment target. Several large epidemiological studies strongly support this concept by finding the apob100:apoai ratio to be superior to lipoprotein measurements as a risk marker. 25 However, important questions remain. For example, is a high ratio caused by low apoai equivalent to a low ratio caused by high apob100? And how would treatment goals be made without the unique information contributed by the apob100/ldl component in comparison to the apoai/hdl? These questions do not have definitive answers, although the role of HDL in reverse cholesterol transport and in maintaining a reduced (not oxidized), state of LDL suggests that risks of elevated LDL can be offset by increased HDL (yet risk would be even further reduced if LDL were lower, and thus the ratio of apob100:apoai were lower). It is critically important to note the values of apob100:apoai and the corresponding TC:HDL ratio that appear to be protective. According to INTERHEART, a large, case-controlled study in almost patients across 52 countries, the average apob100:apoai ratio of ~0.8 (and corresponding TC:HDL ratio of ~5.0) carries a 2-fold relative risk of MI compared to those participants with an apob100:apoai ratio of 0.43 (and corresponding TC:HDL ratio of 2.7). Risks predicted by apob100:apoai were consistently greater than risks predicted by the corresponding ratio of TC:HDL down to an apob100:apoai ratio of 0.6 (and corresponding TC:HDL ratio of 3.8), where the apob100:apoai ratio and TC:HDL ratio predict equivalent risk. 26, 27 This information makes it tempting to rapidly incorporate an apob100:apoai ratio into practice; however, estimates of apob100:apoai ratio risk run nearly parallel with risk predicted by the TC:HDL ratio, with apob100:apoai predicting greater risk, until the apob100:apoai reaches 0.8, where they diverge more sharply. What does this mean? And how does it relate to what to use in practice? The point is that if you are reducing the TC:HDL ratio, you are also reducing the apob100:apoai ratio, and, until you reach a TC:HDL ratio of < 2.7, your patient remains at increased risk. In addition, if your patient s TC:HDL ratio is > 2.7, were you to measure their apob100:apoai ratio, their risk will be even greater than that predicted by TC:HDL. So, clinically, a practitioner should focus on reducing the TC:HDL ratio first, and then fine tune if desired ie, only at that point ordering a single apob100:apoai ratio to confirm optimal risk reduction. Some example scenarios of TC:HDL ratio = 3.0 (for ease) would be: TC = 220, HDL = 73, thus non-hdl = 147; TC = 200, HDL = 67, thus non-hdl = 133; TC = 150, HDL = 50, thus non-hdl = 100. Until you reach these targets, we wouldn t recommend ordering more-expensive testing. However, if you have access to apob100:apoai testing at a comparable cost to your patients, then it is reasonable to use. One final note: Although clinical outcomes based on a reduction of the apob100:apoai ratio are expected to follow risk reductions based on a TC:HDL reduction, this has not been demonstrated in prospective trials. Lipoprotein(a) Lipoprotein(a) Lp(a) is attached to apob. The association of Lp(a) with CAD and its ability to act as a biomarker of risk appears to be strongest in patients with hypercholesterolemia and, in particular, in young patients with premature atherosclerosis (males younger than 55 and females younger than 65). Part of the reason for this is the observation that there seem to be important threshold effects such that only very high Lp(a) levels (> 30 mg/dl) are associated with elevated vascular risk; in this regard, these increased plasma levels of Lp(a) independently predict the presence of CAD, particularly in patients with elevated LDL-C levels. 28 In the Cardiovascular Health Study, a relative risk of approximately 3-fold for death from vascular events and stroke was seen in the highest quintile compared to the lowest quintile of Lp(a) but for males only, whereas no such relation existed for women. 29 Lp(a) is commonly considered a marker for familial hypercholesterolemia. Lp(a) may best be used in assessing the risk of younger males with strong family histories of CVD but should not be used more generally. Other Markers C-reactive protein While it is perhaps incongruous to include highly sensitive C-reactive protein (hscrp), a measure of inflammation, in a review of lipoproteins, we feel it worth brief mention because atherosclerosis does not occur solely as a result of the quantity and quality of lipids in the body. It is generally known that hscrp provides a stable plasma biomarker for low-grade systemic inflammation. It is produced predominantly in the liver as part of the acute phase response; however, hscrp is also expressed in smooth muscle cells within diseased atherosclerotic arteries. Elevated hscrp represents the culmination of numerous proinflammatory pathways and has been implicated in multiple aspects of atherogenesis and plaque vulnerability, including expression of adhesion molecules, induction of nitric oxide, altered complement function, and inhibition of intrinsic fibrinolysis. 2 In a large 10-year cohort study, the relative risk of cardiac death was doubled with increasing hscrp quartiles. Patients in the top quartile (with a mean hscrp of 4.2 mg/dl) had 6 times increased risk compared to the lowest quartile (mean hscrp of 1.20 mg/dl). 30 In addition to lowering LDL-C, hscrp reduction has been hypothesized as an additional mechanism of protection by statin-class lipid-lowering drugs; however, this relationship has not been shown convincingly. Currently, a large multicenter clinical trial (named Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin, or JUPITER) is currently attempting to tease apart the contribution Bradley and Oberg Cardiovascular Disease Integrative Medicine Vol. 7, No. 6 Dec 2008/Jan

5 that lowering CRP has on risk-reduction in patients who have elevated hscrp but not elevated traditional risk factors. Keep your eye out for future mention in the mainstream literature. Lipoprotein-associated phospholipase A 2 Also called platelet-activating factor acetylhydrolase, lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) oxidizes phospholipids, producing a free, oxidized fatty acid and lysophosphatidylcholine both proinflammatory molecules. It exists primarily on LDL particles but also occurs on HDL and in macrophages. 31 Although Lp-PLA 2 traditionally has been considered a biomarker for stroke risk, it may have more clinical utility for general cardiovascular risk than previously thought: The inflammatory cascade initiated by Lp-PLA 2 appears to be ameliorated by such agents as COX-2 and the fibrate drug gemfibrozil, the use of which may provide clinicians with additional treatment strategies by which cardiovascular risk could be reduced. 32,33 In addition, the potential benefit of antioxidant therapy would be a useful area of research. The Big Picture In our efforts to provide the best possible care both for patients with established CVD (high risk) and for those interested in CVD prevention without traditional risk factors (low risk), it is critical first to recognize the contribution of non-lipid CVD risk factors to risk prediction (age, smoking, diabetes history, family history of premature CVD, TC, blood pressure, LDL-C, and HDL-C) and treat to appropriate targets (see Table 2). Relatively rapid risk-prediction tools for use in primary care have been published and can be found online ( gov/health/prof/other/index.htm). 34 To make the point again, additional testing on emerging risk factors should not substitute for accurate risk prediction and treatment based on established risk factors. With this in mind, a reasonable question to ask is when should additional testing be recommended? Table 2. Risk Factors for Cardiovascular Disease (Exclusive of LDL Cholesterol) 34 Cigarette smoking Hypertension (BP > 140/90 mmhg or on antihypertensive medication) Low HDL cholesterol (< 40 mg/dl) Family history of premature CHD (CHD in first-degree male relative < 55 years; CHD in first-degree female relative < 65 years) Age (men > 44 years; women > 54 years) Clinical coronary heart disease, symptomatic carotid artery disease, peripheral arterial disease, or abdominal aortic aneurysm Triglycerides: Technically, TGs are not included in traditional risk calculations, although recent evidence suggests that non-fasting TGs may impact risk, and, as mentioned, hypertriglyceridemia and low HDL-C predict LDL-density patterns; therefore, measurement of TGs in patients with low HDL-C may affect the clinician s choice of lifestyle recommendations. This approach simply measuring TGs is also considerably less costly than LDL-C density-pattern measurement. LDL-C Pattern, Size, and Density: Measurements of LDL-C pattern, size, and density have not convincingly demonstrated unique contributions to cardiovascular risk prediction or, for that matter, to atherogenicity. In fact, as mentioned above, recent analysis refutes the claim of increased atherogenicity of small, dense particles. This conclusion, in combination with high correlations between LDL pattern and levels of HDL and TGs (ie, routinely measured risk factors), led to our deduction that there is limited rationale for ordering these tests, which can be very expensive and confusing for patients. LDL Lipoprotein Particle Number: Given the lack of novel treatments based on LDL-P and the high correlation between LDL-C and LDL-P, it is difficult at this time to recommend routine LDL-P testing. However, it may provide a useful independent assessment of CVD risk when treatment decisions are unclear (ie, with high LDL-C in the presence of high HDL-C, or borderline LDL-C in the presence of non-ldl risk factors). Apolipoproteins: Because apob100 is highly correlated with LDL and VLDL (and therefore with TGs), once again it is difficult to justify apob measurement as a substitute for, or an addition to, routine lipid measurements. Lipoprotein(a): Measurement of Lp(a) should be reserved for the young, male patient with a family history of significant CVD (eg, familial hypercholesterolemia) and/or the patient with premature CAD (males younger than 55 and females younger than 65). C-reactive protein: The hscrp marker is not currently included in risk-prediction calculators. However, we believe that hscrp provides critical information on vascular inflammatory burden, a concept now greatly recognized and understood by most patients, and that it can be used clinically to motivate patients toward smoking cessation and lifestyle change. It is important to note that high levels of hscrp add to risk from elevated LDL-C and/or low HDL-C; low hscrp does not reduce, or supersede, the risk associated with elevated LDL-C. Lipoprotein-associated phospholipase A 2 : It appears that Lp-PLA 2 can provide useful information for clinical decisionmaking because it can be lowered with treatment strategies such as cyclooxygenase inhibitors and second-line lipid-lowering agents such as gemfibrozil that may not be considered for reducing LDL-C. 31, 33 Conclusion In the United States, treatment guidelines for high CVD risk factors are set by the National Cholesterol Education Program (NCEP) Expert Panel, which developed the third report of the Adult Treatment Panel (ATPIII). 34 Treatment goals are determined according to risk stratification by LDL-C and by known additional risk factors such as smoking, low HDL, hypertension, family history, and age. Yet, clinically, decision-making is always more complex than this. Additional risk stratification can be accomplished by measuring the biomarkers discussed above, and this may potentially provide additive benefit beyond NCEP guidelines. However, we always encourage clinicians to treat known risks to goal levels before adding additional goals for treatment. In a future article we will provide further detail on treatment options for novel biomarkers. 22 Integrative Medicine Vol. 7, No. 6 Dec 2008/Jan 2009 Bradley and Oberg Cardiovascular Disease

6 Ryan D. Bradley, ND, is both a clinical scholar and practicing physician. He is a researcher for the Institute for Translational Health Sciences at the University of Washington Medical Center in Seattle and an assistant professor of naturopathic medicine at Bastyr University in Kenmore, Washington. His area of research expertise is the evaluation of biomarkers and treatments for chronic, cumulative oxidation and inflammation in cardiometabolic risk conditions, such as type 2 diabetes and heart disease. In practice, Dr Bradley runs the Diabetes and Cardiovascular Wellness Program, an integrative specialty clinic for diabetes and heart disease, at the Bastyr Center for Natural Health in Seattle. He is also president of Reasonable Remedies LLC. Erica Oberg, ND, MPH, is a senior fellow at the Health Promotion Research Center in the Department of Health Services at the University of Washington in Seattle. Her areas of research expertise are behavioral and lifestyle change in chronic disease and systems improvement for prevention in cardiovascular disease management. She is currently conducting a clinical trial testing the impact of a naturopathic diet in type 2 diabetes. In addition to her research, Dr Oberg is a primary care naturopathic physician at the Institute for Complementary Medicine in Seattle. References 1. No authors listed. Cardiovascular disease statistics. American Heart Association. Available at: Accessed October 28, Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006;47(8 Suppl):C19-C Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297(5): Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94(6): Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3): Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3): Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, lowdensity lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276(11): Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev. 2000;16(2): Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in artherosclerosis. Circulation. 2004;109(23 Suppl 1):III2-III Dormans TP, Swinkels DW, de Graaf J, Hendriks JC, Stalenhoef AF, Demacker PN. Single-spin density-gradient ultracentrifugation vs gradient gel electrophoresis: two methods for detecting low-density-lipoprotein heterogeneity compared. Clin Chem. 1991;37(6): Roheim PS, Asztalos BF. Clinical significance of lipoprotein size and risk for coronary atherosclerosis. Clin Chem. 1995;41(1): Swinkels DW, Demacker PN, Hendriks JC, van t Laar A. Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis. 1989;9(5): Tan CE, Chew LS, Chio LF, et al. Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res Clin Pract. 2001;51(2): Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279(24): St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 2001;104(19): Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192(1): Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298(7): Lewis GF. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr Opin Cardiol. 2006;21(4): Kontush A, de Faria EC, Chantepie S, Chapman MJ. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis. 2005;182(2): Nobécourt E, Jacqueminet S, Hansel B, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia. 2005;48(3): Dungan KM, Guster T, DeWalt DA, Buse JB. A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. Curr Med Res Opin. 2007;23(11): El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49(5): Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2002;22(7): Olofsson SO, Wiklund O, Borén J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag. 2007;3(4): Walldius G, Jungner I. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I new risk factors and targets for therapy. Nutr Metab Cardiovasc Dis. 2007;17(8): Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008;29(7): McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634): Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Metaanalysis of prospective studies. Circulation. 2000;102(10): Ariyo AA, Thach C, Tracy R; Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349(22): Retterstol L, Eikvar L, Bohn M, Bakken A, Erikssen J, Berg K. C-reactive protein predicts death in patients with previous premature myocardial infarction a 10 year follow-up study. Atherosclerosis. 2002;160(2): Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27(8): Kolko M, Rodriguez de Turco EB, Diemer NH, Bazan NG. Neuronal damage by secretory phospholipase A2: modulation by cytosolic phospholipase A2, plateletactivating factor, and cyclooxygenase-2 in neuronal cells in culture. Neurosci Lett. 2003;338(2): Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2008;28(6): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19): Gain library access to 6 years of IMCJ back issues SUBSCRIBE NOW! Don t miss a single issue! Stay abreast of innovative research and cuttingedge information with peer-reviewed, scientifically accurate, practical articles on the integration of conventional and natural medicine. To subscribe, go to Bradley and Oberg Cardiovascular Disease Integrative Medicine Vol. 7, No. 6 Dec 2008/Jan

sad EFFECTIVE DATE: POLICY LAST UPDATED:

sad EFFECTIVE DATE: POLICY LAST UPDATED: Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing

More information

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:

More information

Lipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures

Lipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Lipoprotein Particle Profile

Lipoprotein Particle Profile Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular

More information

Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date

Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with

More information

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,

More information

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,

More information

High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date

High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date MP 2.04.17 High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date

More information

LIPOPROTEIN PROFILING

LIPOPROTEIN PROFILING LIPOPROTEIN PROFILING in CLINICAL DIAGNOSTICS and LIFE SCIENCE RESEARCH Product Information, March 2015 2004-2015, numares HEALTH LIPOPROTEINS AND CARDIOVASCULAR DISEASE High blood cholesterol is a well-known

More information

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised

More information

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

More information

Metabolism and Atherogenic Properties of LDL

Metabolism and Atherogenic Properties of LDL Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal

More information

Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease.

Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease. Michael Garshick, MD PGY-1 Columbia University Medical Center Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease. Study Purpose and Rationale:

More information

Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease

Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;

More information

HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES

HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused

More information

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili

More information

Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date

Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date MP 2.04.22 Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with

More information

Pathophysiology of Lipid Disorders

Pathophysiology of Lipid Disorders Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history

More information

Prof. John Chapman, MD, PhD, DSc

Prof. John Chapman, MD, PhD, DSc Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

Zuhier Awan, MD, PhD, FRCPC

Zuhier Awan, MD, PhD, FRCPC Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier

More information

The apolipoprotein story

The apolipoprotein story Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical

More information

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND

More information

Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease

Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST

More information

Current Challenges in CardioMetabolic Testing. Kenneth French, Director of Clinical Operations

Current Challenges in CardioMetabolic Testing. Kenneth French, Director of Clinical Operations Current Challenges in CardioMetabolic Testing Kenneth French, Director of Clinical Operations Disclosers Employee at VAP Diagnostics Laboratory Outline Cardiometabolic Disease: Current Challenges and Methodology

More information

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Page: 1 of 35 Last Review Status/Date: December 2014 Management of Cardiovascular Disease Description Numerous lipid and nonlipid biomarkers have been proposed as potential risk markers for cardiovascular

More information

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017 Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

10/17/16. Assessing cardiovascular risk through use of inflammation testing

10/17/16. Assessing cardiovascular risk through use of inflammation testing Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response

More information

How to Reduce Residual Risk in Primary Prevention

How to Reduce Residual Risk in Primary Prevention How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with

More information

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism

More information

10/1/2008. Therapy? Disclosure Statement

10/1/2008. Therapy? Disclosure Statement What s New in Lipid Therapy? Brooke Hudspeth, PharmD Diabetes Care Kroger Pharmacy Disclosure Statement In accordance with policies set forth by the Accreditation Council for Continuing Medical Education

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global

More information

Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease

Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST

More information

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients

More information

Placebo-Controlled Statin Trials

Placebo-Controlled Statin Trials PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of

More information

Approach to Dyslipidemia among diabetic patients

Approach to Dyslipidemia among diabetic patients Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences

More information

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives 9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist

More information

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for + Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics

More information

Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003

Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003 Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine

More information

Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III

Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated

More information

Tracking a Killer Molecule

Tracking a Killer Molecule Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

Which CVS risk reduction strategy fits better to carotid US findings?

Which CVS risk reduction strategy fits better to carotid US findings? Which CVS risk reduction strategy fits better to carotid US findings? Dougalis A, Soulaidopoulos S, Cholongitas E, Chalevas P, Vettas Ch, Doumtsis P, Vaitsi K, Diavasti M, Mandala E, Garyfallos A 4th Department

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Dyslipidemia Endothelial dysfunction Free radicals Immunologic ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and

More information

Diabetic Dyslipidemia

Diabetic Dyslipidemia Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals

More information

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Page: 1 of 34 Last Review Status/Date: March 2016 Management of Cardiovascular Disease Description Numerous lipid and nonlipid biomarkers have been proposed as potential risk markers for cardiovascular

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

Hypertriglyceridemia, Inflammation, & Pregnancy

Hypertriglyceridemia, Inflammation, & Pregnancy Hypertriglyceridemia, Inflammation, & Pregnancy Richard L. Nemiroff, MD, FACOG, NLA Professor, Clinical Gynecology Perelman School of Medicine University of Pennsylvania Philadelphia, PA Disclosure of

More information

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal

More information

Best Lipid Treatments

Best Lipid Treatments Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis

More information

The Framingham Coronary Heart Disease Risk Score

The Framingham Coronary Heart Disease Risk Score Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although

More information

Effects of Niacin on LDL Particle Number

Effects of Niacin on LDL Particle Number www.medscape.com Effects of Niacin on LDL Particle Number Haseeb Jafri, Richard H Karas, Jeffrey T Kuvin Clin Lipidology. 2009;4(5):565-571. Abstract and Niacin Overview Abstract Niacin has long been used

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence

More information

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,

More information

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry

More information

Lipid/Lipoprotein Structure and Metabolism (Overview)

Lipid/Lipoprotein Structure and Metabolism (Overview) Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures

More information

Case # 278 Should lipoprotein cholesterol assays disappear?

Case # 278 Should lipoprotein cholesterol assays disappear? Case # 278 Should lipoprotein cholesterol assays disappear? Let's get into the case: I was contacted by a provider who states: "I have a 70 year old guy with absolutely no cardiac risk factors except for

More information

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD 1 Preclinical? No symptoms No physical findings No diagnostic ECG findings No chest X-ray X findings No diagnostic events 2

More information

Glossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"

More information

Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk

Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk cobas modular platform Flexible configurations for tailormade solutions With the cobas modular platform (cobas

More information

CLINICAL OUTCOME Vs SURROGATE MARKER

CLINICAL OUTCOME Vs SURROGATE MARKER CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical

More information

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien

More information

COMPARISON OF APOLIPOPROTEIN CONCENTRATIONS AND VALUES OF APOB:APOAI

COMPARISON OF APOLIPOPROTEIN CONCENTRATIONS AND VALUES OF APOB:APOAI COMPARISON OF APOLIPOPROTEIN CONCENTRATIONS AND VALUES OF APOB:APOAI WITH TRADITIONAL LIPID MEASURES IN WOMEN DIAGNOSED WITH ACUTE CORNONARY SYNDROMES A PRELIMINARY REPORT. Magdalena Krintus, Katarzyna

More information

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Policy Number: 2.04.65 Last Review: 1/2018 Origination: 1/2011 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas

More information

Chapter (5) Etiology of Low HDL- Cholesterol

Chapter (5) Etiology of Low HDL- Cholesterol Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the

More information

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply

More information

Low HDL and Diabetic Dyslipidemia

Low HDL and Diabetic Dyslipidemia The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted

More information

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes

More information

Eyes on Korean Data: Lipid Management in Korean DM Patients

Eyes on Korean Data: Lipid Management in Korean DM Patients Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People

More information

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:

More information

MOLINA HEALTHCARE OF CALIFORNIA

MOLINA HEALTHCARE OF CALIFORNIA MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel

More information

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,

More information

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

Dyslipidemia and the Use of Statins. Troy L Randle, DO, FACC, FACOI

Dyslipidemia and the Use of Statins. Troy L Randle, DO, FACC, FACOI Dyslipidemia and the Use of Statins Troy L Randle, DO, FACC, FACOI Objective: Identify CV risk. Determine what dyslipidemia (dyslipoproteinemia) is Decrease CV risk and optimize lipid levels for your

More information

MEDICAL POLICY SUBJECT: CORONARY CALCIUM SCORING

MEDICAL POLICY SUBJECT: CORONARY CALCIUM SCORING MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV

LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-2011 LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV C. DOBRESCU 1 I. MOLEAVIN 1 Abstract:

More information

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required

More information

For personal use only

For personal use only For mass reproduction, content licensing and permissions contact Dowden Health Media. Apolipoprotein Mature HDL particle Unesterified cholesterol Cholesteryl ester Copyright Dowden Health Media For personal

More information

MEDICAL POLICY. SUBJECT: CARDIOVASCULAR DISEASE RISK ASSESSMENT - LABORATORY EVALUATION OF LIPIDS POLICY NUMBER: CATEGORY: Laboratory Test

MEDICAL POLICY. SUBJECT: CARDIOVASCULAR DISEASE RISK ASSESSMENT - LABORATORY EVALUATION OF LIPIDS POLICY NUMBER: CATEGORY: Laboratory Test MEDICAL POLICY SUBJECT: CARDIOVASCULAR DISEASE RISK PAGE: 1 OF: 10 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

Arteriosclerosis & Atherosclerosis

Arteriosclerosis & Atherosclerosis Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,

More information

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Biochemical Analysis (Lipid Panel) Analyte Total Cholesterol Reference Range Patient A < 200 241 LDL-C /= 40 38 Triglycerides

More information

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol

Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol Patrick R. Lawler, MD, MPH; Akintunde O. Akinkuolie, MBBS,

More information

Lipoprotein (a): Is it important for Friedewald formula?

Lipoprotein (a): Is it important for Friedewald formula? ORIGINAL RESEARCH ALBANIAN MEDICAL JOURNAL Lipoprotein (a): Is it important for Friedewald formula? Murat Can 1, Berrak Guven 1 1 Bulent Ecevit University, Faculty of Medicine, Department of Biochemistry

More information

Do Cholesterol Numbers Really Assess Cardiovascular Risk?

Do Cholesterol Numbers Really Assess Cardiovascular Risk? of people at risk for HEART DISEASE are not identified by routine testing. Visit us at www.spectracell.com Do Cholesterol Numbers Really Assess Cardiovascular Risk? Lipoprotein Particle numbers tell the

More information